Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS)

Sébastien Thureau, Vincent Marchesi, Marie-Hélène Vieillard, Lionel Perrier, Albert Lisbona, Marianne Leheurteur, Jean Tredaniel, Stéphane Culine, Bernard Dubray, Naïma Bonnet, Bernard Asselain, Julia Salleron, Jean-Christophe Faivre, Sébastien Thureau, Vincent Marchesi, Marie-Hélène Vieillard, Lionel Perrier, Albert Lisbona, Marianne Leheurteur, Jean Tredaniel, Stéphane Culine, Bernard Dubray, Naïma Bonnet, Bernard Asselain, Julia Salleron, Jean-Christophe Faivre

Abstract

Background: Stereotactic Body Radiation Therapy (SBRT) is an innovative modality based on high precision planning and delivery. Cancer with bone metastases and oligometastases are associated with an intermediate or good prognosis. We assume that prolonged survival rates would be achieved if both the primary tumor and metastases are controlled by local treatment. Our purpose is to demonstrate, via a multicenter randomized phase III trial, that local treatment of metastatic sites with curative intent with SBRT associated of systemic standard of care treatment would improve the progression-free survival in patients with solid tumor (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases compared to patients who received systemic standard of care treatment alone.

Methods: This is an open-labeled randomized superiority multicenter phase III trial. Patients with up to 3 bone-only metastases will be randomized in a 1:1 ratio.between Arm A (Experimental group): Standard care of treatment & SBRT to all bone metastases, and Arm B (Control group): standard care of treatment. For patients receiving SBRT, radiotherapy dose and fractionation depends on the site of the bone metastasis and the proximity to critical normal structures. This study aims to accrue a total of 196 patients within 4 years. The primary endpoint is progression-free survival at 1 year, and secondary endpoints include Bone progression-free survival; Local control; Cancer-specific survival; Overall survival; Toxicity; Quality of life; Pain score analysis, Cost-utility analysis; Cost-effectiveness analysis and Budget impact analysis.

Discussion: The expected benefit for the patient in the experimental arm is a longer expectancy of life without skeletal recurrence and the discomfort, pain and drastic reduction of mobility and handicap that the lack of local control of bone metastases eventually inflicts.

Trials registration: ClinicalTrials.gov NCT03143322 Registered on May 8th 2017. Ongoing study.

Keywords: Bone metastases; Breast neoplasms; Lung neoplasms; MeSH: Oligometastases; Neoplasm metastasis; Prostatic neoplasms; Radiosurgery; Stereotactic radiotherapy.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Study Design. Footnotes: SBRT: Stereotactic Body radiation Therapy; CT Scan: Computed tomography Scann; PET: Positron Emission Tomography; SPECT-CT: Single Photon Emission Tomography-Computed Tomography

References

    1. Chow E, Hoskin P, Mitera G, Zeng L, Lutz S, Roos D, et al. Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Int J Radiat Oncol Biol Phys. 2012;82(5):1730–1737. doi: 10.1016/j.ijrobp.2011.02.008.
    1. McQuay HJ, Carroll D, Moore RA. Radiotherapy for painful bone metastases: a systematic review. Clin Oncol R Coll Radiol G B. 1997;9(3):150–154. doi: 10.1016/S0936-6555(97)80070-2.
    1. Wu JS-Y, Wong R, Johnston M, Bezjak A, Whelan T. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys. 2003;55(3):594–605. doi: 10.1016/S0360-3016(02)04147-0.
    1. Sze WM, Shelley M, Held I, Mason M. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of the randomised trials. Cochrane Database Syst Rev Online. 2004;2:CD004721.
    1. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A. deSouza NM, et al. characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18–e28. doi: 10.1016/S1470-2045(19)30718-1.
    1. Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2020;148:157–166. doi: 10.1016/j.radonc.2020.04.003.
    1. Ryu S, Rock J, Rosenblum M, Kim JH. Patterns of failure after single-dose radiosurgery for spinal metastasis. J Neurosurg. 2004;101(Suppl 3):402–405. doi: 10.3171/sup.2004.101.supplement3.0402.
    1. Ryu S, Jin R, Jin J-Y, Chen Q, Rock J, Anderson J, et al. Pain control by image-guided radiosurgery for solitary spinal metastasis. J Pain Symptom Manag. 2008;35(3):292–298. doi: 10.1016/j.jpainsymman.2007.04.020.
    1. Ryu S, Jin J-Y, Jin R, Rock J, Ajlouni M, Movsas B, et al. Partial volume tolerance of the spinal cord and complications of single-dose radiosurgery. Cancer. 2007;109(3):628–636. doi: 10.1002/cncr.22442.
    1. Zeng KL, Tseng C-L, Soliman H, Weiss Y, Sahgal A, Myrehaug S. Stereotactic body radiotherapy (SBRT) for Oligometastatic spine metastases: an overview. Front Oncol. 2019;9:337. doi: 10.3389/fonc.2019.00337.
    1. Bedard G, McDonald R, Poon I, Erler D, Soliman H, Cheung P, et al. Stereotactic body radiation therapy for non-spine bone metastases--a review of the literature. Ann Palliat Med. 2016;5(1):58–66.
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376.
    1. Chow E, Hird A, Velikova G, Johnson C, Dewolf L, Bezjak A, et al. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22. Eur J Cancer Oxf Engl 1990. 2009;45(7):1146–1152.
    1. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol group. Ann Med. 2001;33(5):337–343.
    1. Cox BW, Spratt DE, Lovelock M, Bilsky MH, Lis E, Ryu S, et al. International spine radiosurgery consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2012;83(5):e597–e605. doi: 10.1016/j.ijrobp.2012.03.009.
    1. Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008;18(4):215–222. doi: 10.1016/j.semradonc.2008.04.001.
    1. Ryu S, Yoon H, Stessin A, Gutman F, Rosiello A, Davis R. Contemporary treatment with radiosurgery for spine metastasis and spinal cord compression in 2015. Radiat Oncol J. 2015;33(1):1–11. doi: 10.3857/roj.2015.33.1.1.
    1. Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;79(4):965–976. doi: 10.1016/j.ijrobp.2010.11.026.
    1. Costelloe CM, Chuang HH, Madewell JE, Ueno NT. Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer. 2010;1:80–92. doi: 10.7150/jca.1.80.
    1. Lipton A, Costa L, Ali SM, Demers LM. Bone markers in the management of metastatic bone disease. Cancer Treat Rev. 2001;27(3):181–185. doi: 10.1053/ctrv.2000.0212.
    1. Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(3):850–856. doi: 10.1200/JCO.2002.20.3.850.
    1. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337–342. doi: 10.1038/nature01658.
    1. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2(8):584–593. doi: 10.1038/nrc867.
    1. de la Piedra C, Alcaraz A, Bellmunt J, Meseguer C, Gómez-Caamano A, Ribal MJ, et al. Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study. Br J Cancer. 2013;108(12):2565–2572. doi: 10.1038/bjc.2013.270.
    1. Leeming DJ, Koizumi M, Byrjalsen I, Li B, Qvist P, Tankó LB. The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2006;15(1):32–38. doi: 10.1158/1055-9965.EPI-05-0492.
    1. Lein M, Wirth M, Miller K, Eickenberg H-U, Weissbach L, Schmidt K, et al. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol. 2007;52(5):1381–1387. doi: 10.1016/j.eururo.2007.02.033.
    1. Choices in Methods for Economic Evaluation [Internet]. Haute Autorité de Santé. [cited 2020 Jul 18]. Available from:
    1. Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 2005;14(4):339–347. doi: 10.1002/hec.985.
    1. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices--budget impact analysis. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2007;10(5):336–347. doi: 10.1111/j.1524-4733.2007.00187.x.
    1. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of Oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol Off J Am Soc Clin Oncol. 2020;2:JCO2000818.
    1. Boevé LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate Cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. 2019;75(3):410–418. doi: 10.1016/j.eururo.2018.09.008.
    1. Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(12):1992–2003. doi: 10.1093/annonc/mdz396.
    1. Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence. A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(5):446–453. doi: 10.1200/JCO.2017.75.4853.
    1. Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES, et al. A phase II randomized trial of observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE) BMC Cancer. 2017;17(1):453. doi: 10.1186/s12885-017-3455-6.
    1. David S, Tan J, Savas P, Bressel M, Kelly D, Foroudi F, et al. Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: a prospective clinical trial. Breast Edinb Scotl. 2020;49:55–62. doi: 10.1016/j.breast.2019.10.016.
    1. Conibear J, Chia B, Ngai Y, Bates AT, Counsell N, Patel R, et al. Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. BMJ Open. 2018;8(4):e020690. doi: 10.1136/bmjopen-2017-020690.
    1. Al-Shafa F, Arifin AJ, Rodrigues GB, Palma DA, Louie AV. A review of Ongoing trials of stereotactic ablative radiotherapy for Oligometastatic cancers: where will the evidence Lead? Front Oncol. 2019;9:543. doi: 10.3389/fonc.2019.00543.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner